ArticleCureus2026
Validation of the Indonesian Brief Screening Instrument for Epilepsy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Epidemiological studies on epilepsy in Indonesia are scarce, and population-based studies are non-existent. Additionally, no screening questionnaires for epilepsy are available in Indonesia, making future large-scale studies difficult. Therefore, we aimed to validate a short Indonesian screening instrument for epilepsy. Methods An English-language brief screening instrument for the ascertainment of epilepsy was translated into Indonesian through cross-cultural adaptation. The translated questionnaire was distributed to 125 subjects with epilepsy at the neurology clinic in Dr. Cipto Mangunkusumo National Central General Hospital and 125 subjects with no known history of epilepsy for validation. Results The translated Indonesian Brief Screening Instrument for Epilepsy demonstrated good reliability, with an overall Cronbach's alpha of 0.856. A total of 125 cases and 125 controls were analyzed. The sensitivity and specificity of the Indonesian Brief Screening Instrument for Epilepsy varied based on definitions, ranging from 97.6% to 100% and 60.8% to 97.6%, respectively. Under the broadest screen definition, the Indonesian Brief Screening Instrument for Epilepsy achieved 100% sensitivity (95% CI: 97.09-100) and 60.8% specificity (95% CI: 51.67-69.41), with a positive predictive value (PPV) of 1.77% (95% CI: 1.42-2.19) and a negative predictive value (NPV) of 100% (95% CI: 95.26-100). The tool's high NPV indicates strong ability to rule out epilepsy in screen-negative individuals. Conclusion The Indonesian Brief Screening Instrument for Epilepsy is a valid and reliable screening instrument for epidemiological studies in Indonesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.